Cryptococcus neoformans galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy

Immunotherapy

Volumn 3, Issue 8, 2011, Pages 997-1005

  Vecchiarelli, Anna ^a   Pericolini, Eva ^a   Gabrielli, Elena ^a   Chow, Siu Kei ^b   Bistoni, Francesco ^a   Cenci, Elio ^a   Casadevall, Arturo ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

apoptosis; B cell; CD45; galactoxylomannan; macrophage; proliferation; T cell

Indexed keywords

ANTIINFLAMMATORY AGENT; CASPASE 8; FAS LIGAND; GALACTOXYLOMANNAN; IMMUNOMODULATING AGENT; OLIGOSACCHARIDE; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; APOPTOSIS; B LYMPHOCYTE; CELL ACTIVITY; CRYPTOCOCCUS NEOFORMANS; DRUG EFFECT; FUNGAL VIRULENCE; HUMAN; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CRYPTOCOCCUS NEOFORMANS; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MACROPHAGES; POLYSACCHARIDES; T-LYMPHOCYTES;

EID: 80051899985     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.86     Document Type: Review

References (60)

1. Lim TS, Murphy JW. Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect. Immun. 30, 5-11 (1980). (Pubitemid 10018846)
2. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin. Infect. Dis. 19, 1029-1033 (1994). (Pubitemid 24380013)
3. John GT, Mathew M, Snehalatha E et al. Cryptococcosis in renal allograft recipients. Transplantation 58, 855-856 (1994). (Pubitemid 24329194)
4. Goldstein E, Rambo ON. Cryptococcal infection following steroid therapy. Ann. Intern. Med. 56, 114-120 (1962).
5. Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am. J. Epidemiol. 120, 123-130 (1984). (Pubitemid 14076734)
6. Perfect JR, Casadevall A. Cryptococcosis. Infect. Dis. Clin. North Am. 16, 837-874, V-VI (2002). (Pubitemid 35477516)
7. Vecchiarelli A. Immunoregulation by capsular components of Cryptococcus neoformans. Med. Mycol. 38, 407-417 (2000). (Pubitemid 32045754)
8. Monari C, Pericolini E, Bistoni G et al. Influence of indinavir on virulence and growth of Cryptococcus neoformans. J. Infect. Dis. 191, 307-311 (2005). (Pubitemid 40096390)
9. Zaragoza O, Rodrigues ML, De Jesus M et al. The capsule of the fungal pathogen Cryptococcus neoformans. Adv. Appl. Microbiol. 68, 133-216 (2009).
10. Granger DL, Perfect JR, Durack DT. Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J. Clin. Invest. 76, 508-516 (1985). (Pubitemid 15227512)
11. Jacobson ES, Compton GM. Discordant regulation of phenoloxidase and capsular polysaccharide in Cryptococcus neoformans. J. Med. Vet. Mycol. 34, 289-291 (1996). (Pubitemid 26337086)
12. Vartivarian SE, Anaissie EJ, Cowart RE et al. Regulation of cryptococcal capsular polysaccharide by iron. J. Infect. Dis. 167, 186-190 (1993). (Pubitemid 23002855)
13. Guimaraes AJ, Frases S, Cordero RJ et al. Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo. Cell. Microbiol. 12, 740-753 (2010).
14. 2. Infect. Immun. 71, 6155-6164 (2003). (Pubitemid 37337669)
15. Zaragoza O, Casadevall A. Experimental modulation of capsule size in Cryptococcus neoformans. Biol. Proced. Online 6, 10-15 (2004).
16. Heiss C, Klutts JS, Wang Z, Doering TL, Azadi P. The structure of Cryptococcus neoformans galactoxylomannan contains b-d-glucuronic acid. Carbohydr. Res. 344, 915-920 (2009).
17. Gahrs W, Tigyi Z, Emody L, Makovitzky J. Polarization optical analysis of the surface structures of various fungi. Acta Histochem. 111, 308-315 (2009).
18. Frases S, Nimrichter L, Viana NB, Nakouzi A, Casadevall A. Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot. Cell 7, 319-327 (2008). (Pubitemid 351959699)
19. Cherniak R, Morris LC, Belay T, Spitzer ED, Casadevall A. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect. Immun. 63, 1899-1905 (1995).
20. Rachini A, Pietrella D, Lupo P et al. An anti-b-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 75, 5085-5094 (2007). (Pubitemid 350033595)
21. Desnos-Ollivier M, Patel S, Spaulding AR et al. Mixed infections and in vivo evolution in the human fungal pathogen Cryptococcus neoformans. MBio 1(1), E00091-E00010 (2010).
22. Enache-Angoulvant A, Chandenier J, Symoens F et al. Molecular identification of Cryptococcus neoformans serotypes. J. Clin. Microbiol. 45, 1261-1265 (2007). (Pubitemid 46626495)
23. Kwon-Chung KJ, Varma A. Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res. 6, 574-587 (2006). (Pubitemid 43725741)
24. Bose I, Reese AJ, Ory JJ, Janbon G, Doering TL. A yeast under cover: the capsule of Cryptococcus neoformans. Eukaryot. Cell 2, 655-663 (2003). (Pubitemid 36996711)
25. Vaishnav VV, Bacon BE, O'Neill M, Cherniak R. Structural characterization of the galactoxylomannan of Cryptococcus neoformans Cap67. Carbohydr. Res. 306, 315-330 (1998). (Pubitemid 28305000)
26. McFadden DC, De Jesus M, Casadevall A. The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J. Biol. Chem. 281, 1868-1875 (2006). (Pubitemid 43845771)
27. De Jesus M, Chow SK, Cordero RJ, Frases S, Casadevall A. Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable. Eukaryot. Cell 9, 1018-1028 (2010).
28. De Jesus M, Park CG, Su Y et al. Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1. Med. Mycol. 46, 153-162 (2008). (Pubitemid 351372334)
29. James PG, Cherniak R. Galactoxylomannans of Cryptococcus neoformans. Infect. Immun. 60, 1084-1088 (1992).
30. De Jesus M, Nicola AM, Frases S et al. Galactoxylomannan-mediated immunological paralysis results from specific B cell depletion in the context of widespread immune system damage. J. Immunol. 183, 3885-3894 (2009).
31. De Jesus M, Nicola AM, Rodrigues ML, Janbon G, Casadevall A. Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan. Eukaryot. Cell 8, 96-103 (2009).
32. Pericolini E, Cenci E, Monari C et al. Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8. Cell. Microbiol. 8, 267-275 (2006). (Pubitemid 43356049)
33. Pericolini E, Gabrielli E, Cenci E et al. Involvement of glycoreceptors in galactoxylomannan-induced T cell death. J. Immunol. 182, 6003-6010 (2009).
34. Pericolini E, Gabrielli E, Bistoni G et al. Role of CD45 signaling pathway in galactoxylomannan-induced T cell damage. PLoS One 5, E12720 (2010).
35. Kohler B, Anguissola S, Concannon CG et al. Bid participates in genotoxic drug-induced apoptosis of HeLa cells and is essential for death receptor ligands' apoptotic and synergistic effects. PLoS One 3, E2844 (2008).
36. Zhang N, Hartig H, Dzhagalov I, Draper D, He YW. The role of apoptosis in the development and function of T lymphocytes. Cell Res. 15, 749-769 (2005). (Pubitemid 41653913)
37. Krammer PH. CD95's deadly mission in the immune system. Nature 407, 789-795 (2000).
38. Gross A, Yin XM, Wang K et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem. 274, 1156-1163 (1999).
39. Singh R, Pervin S, Chaudhuri G. Caspase-8- mediated BID cleavage and release of mitochondrial cytochrome c during Nomega-hydroxy-l-arginine-induced apoptosis in MDA-MB-468 cells. Antagonistic effects of l-ornithine. J. Biol. Chem. 277, 37630-37636 (2002).
40. Thomas ML. The leukocyte common antigen family. Annu. Rev. Immunol. 7, 339-369 (1989). (Pubitemid 19138017)
41. Irie-Sasaki J, Sasaki T, Penninger JM. CD45 regulated signaling pathways. Curr. Top. Med. Chem. 3, 783-796 (2003).
42. Dang AM, Phillips JA, Lin T, Raveche ES. Altered CD45 expression in malignant B-1 cells. Cell. Immunol. 169, 196-207 (1996). (Pubitemid 26164810)
43. Mustelin T, Tasken K. Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem. J. 371, 15-27 (2003). (Pubitemid 36458075)
44. McNeill L, Salmond RJ, Cooper JC et al. The differential regulation of Lck kinase phosphorylation sites by CD45 is critical for T cell receptor signaling responses. Immunity 27, 425-437 (2007). (Pubitemid 47418669)
45. Zamoyska R, Basson A, Filby A et al. The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunol. Rev. 191, 107-118 (2003). (Pubitemid 36398852)
46. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu. Rev. Immunol. 21, 107-137 (2003). (Pubitemid 37174528)
47. Hermiston ML, Zikherman J, Zhu JW. CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells. Immunol. Rev. 228, 288-311 (2009).
48. Harr MW, Caimi PF, McColl KS et al. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ. 17, 1381-1391 (2010).
49. Gruber C, Henkel M, Budach W, Belka C, Jendrossek V. Involvement of tyrosine kinase p56/Lck in apoptosis induction by anticancer drugs. Biochem. Pharmacol. 67, 1859-1872 (2004). (Pubitemid 38591375)
50. Ledbetter JA, Gentry LE, June CH, Rabinovitch PS, Purchio AF. Stimulation of T cells through the CD3/T-cell receptor complex: role of cytoplasmic calcium, protein kinase C translocation, and phosphorylation of pp60c-src in the activation pathway. Mol. Cell. Biol. 7, 650-656 (1987). (Pubitemid 17004528)
51. Monostori E, Hartyani Z, Ocsovszky I et al. Effect of phytohaemagglutinin on CD45 in T cells. Immunol. Lett. 42, 197-201 (1994). (Pubitemid 24378132)
52. Earl LA, Baum LG. CD45 glycosylation controls T-cell life and death. Immunol. Cell. Biol. 86, 608-615 (2008).
53. Kirchberger S, Majdic O, Bluml S et al. The cytoplasmic tail of CD45 is released from activated phagocytes and can act as an inhibitory messenger for T cells. Blood 112, 1240-1248 (2008).
54. Monari C, Bistoni F, Vecchiarelli A. Glucuronoxylomannan exhibits potent immunosuppressive properties. FEMS Yeast Res. 6, 537-542 (2006). (Pubitemid 43725737)
55. Villena SN, Pinheiro RO, Pinheiro CS et al. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand. Cell. Microbiol. 10, 1274-1285 (2008). (Pubitemid 351663919)
56. Moyrand F, Fontaine T, Janbon G. Systematic capsule gene disruption reveals the central role of galactose metabolism on Cryptococcus neoformans virulence. Mol. Microbiol. 64, 771-781 (2007). (Pubitemid 46653216)
57. Gadebusch HH. Passive immunization against Cryptococcus neoformans. Proc. Soc. Exp. Biol. Med. 98, 611-614 (1958).
58. Gadebusch HH. Active immunization against Cryptococcus neoformans. J. Infect. Dis. 102, 219-226 (1958).
59. Murphy JW, Cozad GC. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect. Immun. 5, 896-901 (1972).
60. Chow SK, Casadevall A. Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis. Vaccine 29, 1891-1898 (2011).